FOXC2 and hepatocellular carcinoma: HCC patients in the FOXC2-Hi group showed more aggressive clinicopathologic characteristics, including higher serum AFP levels, larger tumor size, more recurrence, lower tumor differentiation, and later clinical stage (Table 1).